Entity

Time filter

Source Type

Osaka, Japan

Dainippon Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.The original Dainippon Pharmaceuticals was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku .Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical . Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma. As a result Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014. Wikipedia.


Patent
Dainippon Sumitomo | Date: 2014-02-18

A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1R,2S,3R,4S)-2,3-bicyclo[2,2,1]-heptanedicarboxylmide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.


Patent
Dainippon Sumitomo | Date: 2014-03-11

The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.


Patent
Sunovion Pharmaceuticals and Dainippon Sumitomo | Date: 2015-09-17

Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.


Patent
Sunovion Pharmaceuticals and Dainippon Sumitomo | Date: 2015-09-17

Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.


Patent
Dainippon Sumitomo and International Institute of Cancer Immunology Inc. | Date: 2015-05-07

A compound represented by the formula (1): wherein X wherein X

Discover hidden collaborations